Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated July 21, 2023 under subject 'Intimation of Investor Conference Call on Q1FY24 with Senior Management of Mankind Pharma Limited', the audio recording of the Performance and Business Update Call held today i.e. 03rd August 2023 is available on the website of the Company at https://www.mankindpharma.com/media/investor/kot1320230803148085-orignal-1691059985.mp3
03-08-2023

Mankind Pharma Results Earnings Call for Q1FY24

 Conference Call with Mankind Pharma Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.
03-08-2023
Bigul

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith extracts of the Consolidated Unaudited Financial Results for the quarter ended June 30, 2023 as published in "Financial Express" and "Jansatta" on August 03, 2023.
03-08-2023
Bigul

Q1FY24 Quarterly Result Announced for Mankind Pharma Ltd.

 Pharmaceuticals company Mankind Pharma announced Q1FY24 results: Revenue from operations at Rs 2,579 crore, up by 18% YoY EBITDA at Rs 660 crore, up by 43% YoY with a margin of 25.6% PAT at Rs 494 crore, up by 66% YoY with a margin of 19.2% EPS of Rs 12.1, up by 66% YoY (FV Rs 1) CAPEX of Rs 111 crore Rajeev Juneja – Vice-Chairman & Managing Director, said, “We have started the year on a healthy note, with strong double-digit growth in sales and profitability. The Pharma segment outperformed the IPM by 1.5X led by volume-led growth and highest ever chronic share. Our consumer healthcare segment maintained dominant brand leadership in respective categories. We have also seen positive results from our prior initiatives to improve profitability, with EBITDA growing 43% YoY. Our market disruptive “DMF Quality Products” campaign has seen an outstanding response and we are rapidly expanding our product offerings in this important initiative. Our strategic initiatives across the businesses are delivering positive results and we are hopeful that we will continue to outperform industry growth, going ahead." Result PDF
03-08-2023

Mankind Pharma share price jumps over 8% on robust Q1 results

 Mankind Pharma stock price jumps 8% after strong Q1FY24 results, reaching near 52-week high level.
03-08-2023
Bigul

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release on Financial Results for the quarter ended June 30, 2023.
02-08-2023
Bigul

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Investor Presentation of Q1FY2023-24
02-08-2023
Bigul

Mankind Pharma Ltd - 543904 - Outcome Of Board Meeting

 The Board at its meeting held on 02nd August, 2023 has inter alia approved the following: 1. Re-appointment of Mr. Ramesh Juneja as Chairman and Whole Time Director. 2. Re-appointment of Mr. Rajeev Juneja as Vice Chairman and Managing Director. 3. Re-appointment of Mr. Sheetal Arora as Whole-time Director and Chief Executive Officer. 4. Re-designation of Mr. Suresh Raju Penmetsa as Chief Risk Officer and Vice President EHS. 5. Re-appointment of M/s Dayal & Maur, Company Secretaries as the Secretarial Auditor of the Company for the FY 2023-24. 6. Ratification of Mankind Employee Stock Option Plan 2022. 7. Ratification of grant of employee stock option to the employees of subsidiary company(ies)/Group Company/ Associate Companies. Item no. 1, 2, 3, 6 and 7 are subject to approval of the members of the Company.
02-08-2023
Bigul

Mankind Pharma Ltd - 543904 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. August 2, 2023

 Outcome of Board Meeting as per letter attached
02-08-2023
Bigul

Mankind Pharma Ltd - 543904 - Regulation 30 And 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Outcome of Board Meeting as per letter attached.
02-08-2023
Next Page
Close

Let's Open Free Demat Account